CAR T cell therapies are living drugs that use genetically modified T cells to recognize and attack cancer cells. A critical component for ensuring the efficacy of these therapies are potency assays that measure CAR T cells’ efficacy in killing their target cells such as transformed B-cells in the case of Yescarta and Kymriah. The […]
Since January 22nd, 2026, Accellix is part of bioMérieux, a world leader in the field of in vitro diagnostics.
Learn more about this strategic acquisition.
Uncategorized
Ensuring CAR T Cell Quality: Validating a Potency Assay to Current Regulatory Standards
August 23, 2024 | 14 min read
